USA - NASDAQ:AMRN - US0231114044 - ADR
Taking everything into account, AMRN scores 3 out of 10 in our fundamental rating. AMRN was compared to 536 industry peers in the Biotechnology industry. The financial health of AMRN is average, but there are quite some concerns on its profitability. AMRN is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -15.46% | ||
ROE | -22.28% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 54.1% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -1.75 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.26 | ||
Quick Ratio | 2.34 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
16
+0.55 (+3.56%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 1.51 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.71 | ||
P/tB | 0.74 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -15.46% | ||
ROE | -22.28% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 54.1% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 3.26 | ||
Quick Ratio | 2.34 | ||
Altman-Z | -1.75 |